COVID-19 Drug Treatment in China

Abstract

Purpose of Review

An unprecedented outbreak of the novel coronavirus in China (COVID-19) occurred in December 2019, and then engulfed the entire world, presenting a significant and urgent threat to global health. Many research institutes have been involved in the development of drugs and vaccines against COVID-19.

Recent Findings

At present, the strategy of new use of old drugs is mainly used to screen candidate drugs against the novel coronavirus (later termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) and inhibit excessive immune response. Related research has made great progress.

Summary

In this review, we summarize the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hoped that this review will be useful to provide guidance for the prevention, treatment, and control of COVID-19.

Introduction

An outbreak of a series of pneumonia cases associated with a novel coronavirus has been reported in Wuhan, Hubei Province, China, since December 2019 [1,2,3]. It is highly contagious and has rapidly spread to the entire China and multiple other countries worldwide since then [4,5,6]. On January 5, 2020, Professor Zhang of Fudan University completed virus sequencing and submitted the first novel coronavirus genome sequence to the National Bank of the US National Center for Biotechnology Information (Acc. No. MN908947). After that, this global health threat was officially and internationally named SARS-CoV-2 by the World Health Organization (WHO) on February 11, 2020 [7]. On January 30, 2020, the WHO declared the Chinese outbreak of COVID-19 to be a public health emergency of international concern, which means the outbreak of COVID-19 raised intense attention internationally; all countries around the world should be prepared for a potential global outbreak [8,9,10]. Up to now, there had been 1,524,334 confirmed cases, 340,335 cured, and 88,468 deaths (as of April 9, 2020). Clinically, most patients developed mild symptoms of dry cough, dyspnea, fever, and bilateral lung infiltrates on imaging [11,12,13]. Besides, numbers of researches have confirmed that while the mortality rate of the elderly and patients with underlying diseases is high, that of the young is relatively low through the deadliest outbreak of COVID-19 [14].

There are six strains of coronaviruses that are confirmed infectious to humans, which are named for their coronary appearance with positive single-stranded RNA genomes [15]. Similar to SARS and MERS, SARS-CoV-2 is a kind of highly pathogenic coronavirus that could cause severe respiratory illness and even death [16]. However, SARS-CoV-2 has higher transmissibility from human to human comparatively, which makes humans vulnerable to infection and makes it harder to get this outbreak under control [17,18,19].

As the epidemic is getting worse, the control of COVID-19 presents multiple challenges in the short term [20]. Nevertheless, no specific antiviral medicine is available either to treat or to prevent the aggravation of COVID-19 [21, 22]. More potent antiviral drugs are urgent to be developed [23]. It usually takes about 12 to 15 years for a new drug transitioning from development to market, which is a fairly long process. Therefore, it is not feasible to study antinovel coronavirus drugs from the beginning to get a direct effect on the prevention and control of this outbreak. Only by adopting the strategy of “old drugs for new use,” that is, finding effective drugs against novel coronavirus from existing drugs on the market, making it be rapidly applied to clinical practice [24, 25]. COVID-19’s therapeutic strategies mainly relied on the experience of clinicians [26, 27]. Up to now, some medicines are confirmed clinically to be effective in eliminating SARS-CoV-2 and improving symptoms [28, 29]. Among them, traditional Chinese medicines have received broad adoption, especially in treating cases of mild symptoms [30, 31]. In this review, we summarized the drugs used for COVID-19 treatment in China based on the emerging basic and clinical data. It is hopeful that this review will be useful to provide guidance for the prevention and control of COVID-19.

Traditional Chinese Medicine

Although there is no specific medicine recommended to prevent or treat the novel coronavirus to date, when the outbreak started, Chinese medicine (CM) approaches including oral administration of preventive herbal formulae, wearing CM sachets, and indoor herbal medicine fumigation were recommended for prevention and treatment and have shown pretty good effects [32, 33]. Under the guidance of clinical experience, the treatment for COVID-19 was divided into medical observation period and clinical treatment period (confirmed cases). The clinical treatment period (confirmed cases) is further stratified into four manifestations including mild case (cold-damp constraint in the lung pattern or damp-heat accumulation in the lung pattern), moderate case (damp-toxin constraint in the lung pattern or cold-damp obstructing the lung pattern), severe case (epidemic toxin blocking the lung pattern or blazing of both Qi and Ying patterns), and critical case (internal blockage and external desertion pattern) followed by a rehabilitation stage (lung and spleen qi deficiency patterns or deficiency of both qi and yin patterns). Depending on the patient’s pathological condition, different medications or prescriptions were used at different stages [30, 34]. At present, a total of 23 different Chinese medicines are recommended nationwide for the treatment of mild, severe, and critical symptoms [35]. According to prescriptions and standards, under the guidance of traditional Chinese medicine theory, Chinese medicines were made into certain dosage forms, which could be directly used for the prevention and treatment of diseases [36,37,38,39,40,41,42]. Those Chinese medicine formulation used on COVID-19 are listed in Table 1.

Table 1 Reported use of Chinese medicine formulations on COVID-19

Chemical Medicine

Lopinavir/Ritonavir

Lopinavir/ritonavir tablets (trade name: Cleeve) are broad-spectrum antiviral drugs developed by AbbVie Inc., which was first approved by the European Union in 2001 [43, 44]. It is a type of human immunodeficiency virus (HIV) protease inhibitor that can block the cleavage of Gag-Pol precursor protein into mature protein, which eventually leads to the production of immature and non-infectious virus particles [45, 46]. It has been confirmed that ritonavir is an active peptidomimetic inhibitor against HIV-1 and HIV-2 aspartyl proteases. The enzyme cannot cleave the Gag-Pol precursor protein by inhibiting HIV protease which could lead to the formation of immature forms of HIV particles and prevent a new round of infection [47]. Currently, in vitro studies have shown that lopinavir/ritonavir can inhibit the replication of Middle East respiratory syndrome coronavirus (MERS-CoV) and severe acute respiratory syndrome coronavirus (SARS-CoV) to exert antiviral effects [48]. Based on that, lopinavir/ritonavir has been recommended for the clinical treatment of COVID-19 in China. According to the advantages of lopinavir/ritonavir in antiviral therapy, it is suggested that lopinavir/ritonavir should use in the early period of antiviral treatment to improve clinical symptoms and reduce viral load. The oral dosage is recommended once a day (800 mg/200 mg) that may increase treatment compliance, reduce adverse reactions, control the spread through urine and feces, and hinder the spread of the epidemic [32, 49]. However, the latest research has reported that lopinavir/ritonavir treatment did not significantly accelerate clinical improvement, reduce mortality, or diminish throat viral RNA detectability in patients with COVID-19 [50]. Besides, it should be noted that lopinavir/ritonavir is an inhibitor of liver P450 isoenzyme CYP3A. When it is combined with drugs that are mainly metabolized by CYP3A, it may lead to increased blood concentration of the combining drugs, which increases the adverse reaction.

Ribavirin

Ribavirin is a synthetic nucleoside antiviral drug with broad-spectrum antiviral activity, which inhibits both DNA and RNA viruses and widely used for the treatment of SARS and MERS [43, 51,52,53]. It was recommended that the combined use of ribavirin and α-interferon or lopinavir, 500 mg/time for adults with 2 to 3 intravenous injections per day, could control and improve patient’s condition, but the therapeutic process should be limited to 10 days [32]. Notably, patients with contraindications should be excluded before clinical application for the reason that the incidence of adverse reactions of ribavirin is high and the individualized differences are obvious [54]. Studies on the effect of ribavirin in vitro showed that ribavirin could reduce viral infection [55]. However, the effectiveness and safety of ribavirin for COVID-19 still need further clinical trials to confirm. Medical workers should carefully and comprehensively evaluate the patient’s various indicators to ensure the safety of patients’ medication.

Arbidol

Arbidol is a non-nucleoside antiviral drug developed by the research center for pharmaceutical chemistry of the Soviet Union. Arbidol exerts an antiviral effect by inhibiting the fusion of the viral lipid membrane with the host cell to block the replication of the virus [56, 57]. It is active against many enveloped and non-enveloped viruses and has an interferon-inducing effect [58]. It has been found that 10–30 μmol of arbidol could effectively inhibit SARS-CoV-2 proliferation by 60 times compared with a drug-untreated control group and significantly inhibit the pathological effects of viruses in vitro [54, 59].

Remdesivir

Remdesivir is a nucleoside drug and an RNA polymerase (RdRp) inhibitor which was developed by Gilead Sciences in the USA [60, 61]. Accumulating evidence indicates that remdesivir could inhibit virus replication and play an antiviral role through blocking the synthesis of negative-strand RNA by inhibiting SARS-CoV-2 RdRp, subgenomic mRNA, and subviral genomic RNA [62, 63]. Remdesivir has shown good anti-MERS-CoV and anti-SARS-CoV activities in vitro and in animal models [64] and has anti-SARS-CoV-2 activity in vitro, indicating it could be used as a potential anti-SARS-CoV-2 drug [65]. On January 31, 2020, the prestige medical journal “New England Medical Journal” (NEJM) reported the diagnosis and treatment process of the first SARS-CoV-2 infected patient in the USA, showing that remdesivir has a certain role in the treatment [25, 54, 66]. Cell research published an article stating that among the six antiviral drugs tested, remdesivir had the strongest inhibitory effect of COVID-19 in vitro (EC50 = 0.77 μmol/L) [32]. Currently, remdesivir’s clinical trials have been officially launched in China that a total of 761 patients are planned to be included in this study.

Favipiravir

Favipiravir is a wide-spectrum nucleoside antiviral drug developed by FUJIFILM Toyama Chemical Co., Ltd. [67]. It is a precursor drug that could be metabolized into the active metabolite favipiravir-ribofuranosyl-5′-triphosphate (favipiravir-rtp) in vivo, which has an inhibitory effect on the RNA virus RdRp. The drug’s initial indication was against influenza [68]. But subsequent studies have shown that the drug has inhibitory activity against almost all RNA viruses, such as West Nile virus, yellow fever virus, enterovirus, and Ebola virus [69,70,71,72]. On February 15, 2020, favipiravir tablets were marketed in China, and the indication was approved for the treatment of new or recurrent epidemics in adults. Thus, favipiravir became a potential drug for treatment of COVID-19 patients [73]. In a small-scale clinical trial of COVID-19, favipiravir has shown promising efficacy and low adverse reactions. It has been shown that favipiravir is effective against SARS-CoV-2 (EC50 = 61.88 μmol/L) [32].

Darunavir

Darunavir is an inhibitor of protease dimerization and catalytic activity of HIV-1 [74, 75]. It can selectively inhibit the cleavage of HIV encoded gag-pol precursor protein in virus infected cells, thus blocking the formation of mature infectious virus particles [76, 77]. Clinically, darunavir is mainly used as a drug for AIDS. On February 4, 2020, it was announced that darunavir could significantly inhibit the replication of the virus at concentration of 300 μmol/L [32, 54].

Emtricitabine and Denofovir Alafenamide

Emtricitabine is a nucleoside reverse transcriptase inhibitor which is used in AIDS treatment [78, 79]. It blocks the reverse transcription process of HIV by inhibiting reverse transcriptase and can also effectively inhibit hepatitis B virus (HBV) reverse transcription process [77, 80]. It has been reported that the combination of emtricitabine and denofovir alafenamide in clinical trial for the treatment of COVID-19 was applied with great therapeutic effects [32].

Chloroquine Phosphate

Chloroquine phosphate is mainly used in the treatment of malaria and rheumatism in clinical [81,82,83]. Numerous studies have presented that it has broad-spectrum antiviral effect [84]. Recently, it has been found that chloroquine phosphate could effectively inhibit the infection of coronavirus at the cellular level [85,86,87]. It has been recommended for antiviral treatment of the COVID-19 as well [88].

Hydroxychloroquine

Hydroxychloroquine was developed as an antimalarial drug and has been used for the treatment of rheumatoid arthritis and lupus erythematosus [89,90,91]. Due to its antiviral activity, hydroxychloroquine has also been used as an adjuvant therapy for AIDS [92,93,94]. It has been confirmed that hydroxychloroquine also has therapeutic effect against Ebola virus and dengue virus in in vitro studies [95]. Recently, it has been reported that some COVID-19 patients benefited from the treatment with hydroxychloroquine [96,97,98,99]. Moreover, its effect for virus elimination could be reinforced by azithromycin [97].

Biological Medicine

Interferon α

Interferon (IFN) is a kind of multifunctional cytokine family with broad-spectrum antiviral, antiproliferative, and immunomodulatory activities. According to different binding receptors, it can be divided into type I, type II, and type III. Among them, type II IFN (mainly α/β IFN) plays an important role in the control of virus infection. Naturally, IFN-α is a very important immune protective cytokine in human response to virus infection [100, 101]. It could induce the same cell to produce antiviral protein and limit the further replication and spread of the virus [102, 103]. Moreover, IFN-α has been recommended to be applied in the treatment of COVID-19 recently [32].

Tocilizumab Injection

Tocilizumab injection is a recombinant humanized monoclonal antibody against human IL-6 receptor, which specifically binds to soluble and membranous IL-6 receptor to block signal transduction, thus inhibiting the activity of IL-6 receptor and achieving the goal of treating rheumatoid arthritis [104,105,106]. IL-6R plays an important role in the occurrence and development of some inflammatory and autoimmune diseases. As an activator of IL-6, sIL-6R can enhance the sensitivity of cells to IL-6 [107]. It has been found that as an antagonist of cytokine interleukin-6 (IL-6), tocilizumab injection is likely to block cytokine storm and thus prevent COVID-19 patients from turning to severe and critical diseases [108]. Tocilizumab injection has been recommended as a treatment for COVID-19 by researchers at University of Science and Technology of China.

Glucocorticoids

Glucocorticoid is an extremely important regulatory molecule in the human body [109]. It plays an important role in regulating the body’s development, growth, metabolism, and immune function. It is the most important regulatory hormone in the body’s stress response, and it is also the most widely used and effective antiinflammatory and immunosuppressive agent in clinical practice [110, 111]. During the treatment of COVID-19, it is recommended to be used for severe cases with high inflammatory response or children with acute respiratory distress syndrome [32, 112]. However, the side effects of glucocorticoids are severe; WHO recommends that glucocorticoids are not suitable for the routine treatment of COVID-19 except in clinical trials [11, 113, 114].

Convalescent Plasma Therapy

Currently, the convalescent plasma therapy has been in the process of promotion; some patients’ clinical indicators and symptoms have been improved [32]. There have been a large number of people who have recovered from coronavirus infection, donating valuable serum containing immunoglobulin which seems better than trying to produce large amounts of monoclonal antibodies in the laboratory. However, using antibodies to treat COVID-19 has some obvious problems such as limited sources of therapeutic plasma, different concentrations and activities of antibodies in human plasma of various sources, and non-neutralizing antibodies in plasma that may contribute to cytokine storms and other safety risks. Therefore, the convalescent plasma therapy is only used on a small scale, while large-scale use still needs to wait until we understand the clinical application effect and adverse reactions. The safety and efficacy of convalescent plasma transfusion in SARS-CoV-2-infected patients should be studied within the context of a well-designed clinical trial. In the absence of vaccines and specific therapeutic drugs, the recovery plasma therapy is still an exploratory treatment. The current diagnosis and treatment scheme is recommended to try in severe patients and closely monitor the possible risks [115].

Other Biological Medicine

There are also other biological medicines on COVID-19 such as human immunoglobulin and intestinal microecological regulator. Some researchers in China have suggested that human immunoglobulins can be selectively used to treat critically patients. Intravenous immunoglobulin in large doses could be used for severe systemic inflammatory response syndrome [11]. It has been suggested that intestinal microecological regulator could maintain intestinal microecological balance and prevent secondary bacterial infection [32].

Perspective

As for a new emerging acute infectious disease caused by SARS-CoV-2, there are still no specific antiviral drugs. All options for its prevention and treatment are based on previous experience in the treatment of SARS, MERS, or other new influenza viruses. Active treatment based on the patient’s symptoms is still the main direction of treatment. Up to now, China has made a great breakthrough in fighting against COVID-19, but the situation outside China is not optimistic. The Chinese Health Commission has established several versions of diagnosis and treatment plans on COVID-19, which was formulated in a short time by professionals in various fields. But it is just a temporary solution at present. Since these drugs were not developed for the treatment of COVID-19, the clinical therapeutic effect is surely limited. Besides, the efficacy and safety of involved medicines still need to be confirmed in further clinical treatment and research. Even though those medicines we used have certain therapeutic effect, it is still urgent for medical researchers to carry on the research and development of specific medicine and vaccine according to the infection mechanism and characteristic structure of new crown virus. What is more, an effective mechanism for drug development of coronavirus should be established.

Currently, the enthusiasm for COVID-19 drug research runs high, but whether long-term scientific research can persist after the epidemic is a bit more in doubt. The isolation and structure analysis of various coronaviruses have been completed in early period, but there is still no specific drug for each coronavirus in the world. The reasons are as follows: firstly, the replication mutation rate of the virus is very high, and it is easy to produce drug-resistant strains. Secondly, after the acute infectious period of a novel coronavirus, the patient is likely to have developed a corresponding durable immunity. However, compared with the transient infection of virus epidemic, the new drug development cycle is fairly a long time, which is not suitable for the development of coronavirus drugs economically. Therefore, the joint efforts of government departments and drug research and development departments are needed to achieve a breakthrough in a short period of time, for accumulating experience of the possible future coronavirus epidemic.

Conclusions

The drugs used for COVID-19 treatment in China based on the emerging basic and clinical data were summarized above. Among them, Chinese medicines have received broad adoption, especially in treating cases of mild symptoms. There is still a lot for us to do in the face of COVID-19. It is hoped that this review will be useful to provide guidance for the prevention and control of COVID-19.

References

  1. 1.

    Ksiazek TG, Erdman D, Goldsmith CS, Zaki SR, Peret T, Emery S, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953–66.

    CAS  PubMed  Google Scholar 

  2. 2.

    Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol. 2020;92(4):401–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–33.

    CAS  PubMed  PubMed Central  Google Scholar 

  4. 4.

    Bastola A, Sah R, Rodriguez-Morales AJ, Lal BK, Jha R, Ojha HC, et al. The first 2019 novel coronavirus case in Nepal. Lancet Infect Dis. 2020;20(3):279–80.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. 5.

    Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382(10):929–36.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. 6.

    Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. Jama. 2020;323:1335.

    Google Scholar 

  7. 7.

    Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. 8.

    Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Salzberger B, Glück T, Ehrenstein B. Successful containment of COVID-19: the WHO-report on the COVID-19 outbreak in China. Infection. 2020;48(2):151–3.

    CAS  Google Scholar 

  10. 10.

    Silverstein WK, Stroud L, Cleghorn GE, Leis JA. First imported case of 2019 novel coronavirus in Canada, presenting as mild pneumonia. Lancet. 2020;395((10225)):734.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Wang D; Hu B; Hu C; Zhu F; Liu X; Zhang J; Wang B; Xiang H; Cheng Z; Xiong Y; Zhao Y; Li Y; Wang X; Peng Z Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama 2020.

  12. 12.

    Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Henry BM; Vikse J Clinical characteristics of Covid-19 in China. N Engl J Med 2020, 382.

  14. 14.

    Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8:420–2.

    CAS  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130–7.

    PubMed  Google Scholar 

  16. 16.

    Liu Y; Gayle AA; Wilder-Smith A; Rocklöv J The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med 2020, 27, (2).

  17. 17.

    Chan JF, Yuan S, Kok KH, To, K. K, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 2020;382(9):872–4.

    PubMed  PubMed Central  Google Scholar 

  19. 19.

    Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382(13):1199–207.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and COVID-19: the most important research questions. Cell Biosci. 2020;10:40.

    PubMed  PubMed Central  Google Scholar 

  21. 21.

    Patel A, Jernigan DB. Initial Public Health Response and Interim Clinical Guidance for the 2019 Novel coronavirus outbreak - United States, December 31, 2019-February 4, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(5):140–6.

    PubMed  PubMed Central  Google Scholar 

  22. 22.

    Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020;382:1851–2.

    PubMed  Google Scholar 

  23. 23.

    Kupferschmidt K, Cohen J. Race to find COVID-19 treatments accelerates. Science. 2020;367(6485):1412–3.

    CAS  PubMed  Google Scholar 

  24. 24.

    Cunningham AC, Goh HP, Koh D. Treatment of COVID-19: old tricks for new challenges. Crit Care. 2020;24(1):91.

    PubMed  PubMed Central  Google Scholar 

  25. 25.

    Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69–71.

    CAS  PubMed  Google Scholar 

  26. 26.

    Raoult D; Hsueh PR; Stefani S; Rolain JM, COVID-19 therapeutic and prevention. Int J Antimicrob Agents 2020, 105937.

  27. 27.

    Wu J; Li W; Shi X; Chen Z; Jiang B; Liu J; Wang D.; Liu C; Meng Y; Cui L; Yu J; Cao H; Li L, Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med 2020.

  28. 28.

    Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health. 2020;8:e639–40.

    PubMed  PubMed Central  Google Scholar 

  29. 29.

    Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest. 2020;130:2202–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res. 2020;155:104743.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. 31.

    Guidance for corona virus disease 2019: prevention, control, diagnosis and management. 2020, (People's Medical Publishing House), 146.

  32. 32.

    Chan KW, Wong VT, Tang SCW. COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 novel coronavirus disease. Am J Chin Med. 2020:1–26.

  33. 33.

    Luo H, Tang QL, Shang YX, Liang SB, Yang M, Robinson N, et al. Can Chinese medicine be used for prevention of corona virus disease 2019 (COVID-19)? A review of historical classics, research evidence and current prevention programs. Chin J Integr Med. 2020:1–8.

  34. 34.

    Wan S; Xiang Y; Fang W; Zheng Y; Li B; Hu Y; Lang C; Huang D; Sun Q; Xiong Y; Huang X; Lv J; Luo Y; Shen L; Yang H; Huang G; Yang R, Clinical features and treatment of COVID-19 patients in Northeast Chongqing. J Med Virol 2020.

  35. 35.

    Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020;14(1):64–8.

    CAS  Google Scholar 

  36. 36.

    Runfeng L; Yunlong H; Jicheng H; Weiqi P; Qinhai M; Yongxia S; Chufang L; Jin Z; Zhenhua J; Haiming J; Kui Z; Shuxiang H; Jun D; Xiaobo L; Xiaotao H; Lin W; Nanshan Z; Zifeng Y, Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020, 104761.

  37. 37.

    He J, Li Z, Huang W, Guan W, Ma H, Yang ZF, et al. Efficacy and safety of Chou-Ling-Dan granules in the treatment of seasonal influenza via combining Western and traditional Chinese medicine: protocol for a multicentre, randomised controlled clinical trial. BMJ Open. 2019;9(4):e024800.

    PubMed  PubMed Central  Google Scholar 

  38. 38.

    Ma Q; Yu Q; Xing X; Liu S; Shi C; Luo J, San Wu Huangqin Decoction, a Chinese herbal formula, inhibits influenza a/PR/8/34 (H1N1) virus infection in vitro and in vivo. Viruses 2018, 10, (3).

  39. 39.

    Yin J, Ma L, Wang H, Yan H, Hu J, Jiang W, et al. Chinese herbal medicine compound Yi-Zhi-Hao pellet inhibits replication of influenza virus infection through activation of heme oxygenase-1. Acta Pharm Sin B. 2017;7(6):630–7.

    PubMed  PubMed Central  Google Scholar 

  40. 40.

    Zou W, Wang J, Liu Y. Effect of traditional Chinese medicine for treating human immunodeficiency virus infections and acquired immune deficiency syndrome: boosting immune and alleviating symptoms. Chin J Integr Med. 2016;22(1):3–8.

    CAS  PubMed  Google Scholar 

  41. 41.

    Wang L, Yang R, Yuan B, Liu Y, Liu C. The antiviral and antimicrobial activities of licorice, a widely-used Chinese herb. Acta Pharm Sin B. 2015;5(4):310–5.

    PubMed  PubMed Central  Google Scholar 

  42. 42.

    Hsieh YJ, Yen MH, Chiang YW, Yeh CF, Chiang LC, Shieh DE, et al. Gan-Lu-Siao-Du-yin, a prescription of traditional Chinese medicine, inhibited enterovirus 71 replication, translation, and virus-induced cell apoptosis. J Ethnopharmacol. 2016;185:132–9.

    PubMed  Google Scholar 

  43. 43.

    Totura AL, Bavari S. Broad-spectrum coronavirus antiviral drug discovery. Expert Opin Drug Discovery. 2019;14(4):397–412.

    Google Scholar 

  44. 44.

    Lopinavir. In LiverTox: clinical and research information on drug-induced liver injury, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD), 2012.

  45. 45.

    Canals F, Masiá M, Gutiérrez F. Developments in early diagnosis and therapy of HIV infection in newborns. Expert Opin Pharmacother. 2018;19(1):13–25.

    PubMed  Google Scholar 

  46. 46.

    Coelho AV; Tricarico PM; Celsi F; Crovella S, Antiretroviral treatment in HIV-1-positive mothers: neurological implications in virus-free children. Int J Mol Sci 2017, 18, (2).

  47. 47.

    Barlow-Mosha L, Angelidou K, Lindsey J, Archary M, Cotton M, Dittmer S, et al. Nevirapine- versus lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: long-term follow-up of the IMPAACT P1060 randomized trial. Clin Infect Dis. 2016;63(8):1113–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Mo Y, Fisher D. A review of treatment modalities for Middle East respiratory syndrome. J Antimicrob Chemother. 2016;71(12):3340–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  49. 49.

    Martinez MA, Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 2020, 64.

  50. 50.

    Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M.; Li, X.; Xia, J.; Chen, N.; Xiang, J.; Yu, T.; Bai, T.; Xie, X.; Zhang, L.; Li, C.; Yuan, Y.; Chen, H.; Li, H.; Huang, H.; Tu, S.; Gong, F.; Liu, Y.; Wei, Y.; Dong, C.; Zhou, F.; Gu, X.; Xu, J.; Liu, Z.; Zhang, Y.; Li, H.; Shang, L.; Wang, K.; Li, K.; Zhou, X.; Dong, X.; Qu, Z.; Lu, S.; Hu, X.; Ruan, S.; Luo, S.; Wu, J.; Peng, L.; Cheng, F.; Pan, L.; Zou, J.; Jia, C.; Wang, J.; Liu, X.; Wang, S.; Wu, X.; Ge, Q.; He, J.; Zhan, H.; Qiu, F.; Guo, L.; Huang, C.; Jaki, T.; Hayden, F. G.; Horby, P. W.; Zhang, D.; Wang, C., A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med 2020.

  51. 51.

    Jordan PC, Stevens SK, Deval J. Nucleosides for the treatment of respiratory RNA virus infections. Antivir Chem Chemother. 2018;26:2040206618764483.

    CAS  PubMed  PubMed Central  Google Scholar 

  52. 52.

    Rabaan AA, Alahmed SH, Bazzi AM, Alhani HM. A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective. J Med Microbiol. 2017;66(9):1261–74.

    CAS  PubMed  PubMed Central  Google Scholar 

  53. 53.

    Al-Tawfiq JA, Memish ZA. Update on therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV). Expert Rev Anti-Infect Ther. 2017;15(3):269–75.

    CAS  PubMed  Google Scholar 

  54. 54.

    Zhang C, Huang S, Zheng F, Dai Y. Controversial treatments: an updated understanding of the coronavirus disease. J Med Virol. 2019:2020.

  55. 55.

    Feld JJ, Bernstein DE, Younes Z, Vlierberghe HV, Larsen L, Tatsch F, et al. Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin. Liver Int. 2018;38(9):1571–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  56. 56.

    Blaising J, Polyak SJ, Pécheur EI. Arbidol as a broad-spectrum antiviral: an update. Antivir Res. 2014;107:84–94.

    CAS  PubMed  Google Scholar 

  57. 57.

    Abdelnabi R, Neyts J, Delang L. Towards antivirals against chikungunya virus. Antivir Res. 2015;121:59–68.

    CAS  PubMed  Google Scholar 

  58. 58.

    Teissier E, Penin F, Pécheur EI. Targeting cell entry of enveloped viruses as an antiviral strategy. Molecules. 2010;16(1):221–50.

    PubMed  PubMed Central  Google Scholar 

  59. 59.

    Deng L; Li C; Zeng Q; Liu X; Li X; Zhang H; Hong Z; Xia J, Arbidol combined with LPV/r versus LPV/r alone against corona virus disease 2019: a retrospective cohort study. J Inf Secur 2020.

  60. 60.

    Gordon C J; Tchesnokov EP; Feng JY; Porter DP; Gotte M, The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 2020.

  61. 61.

    Tchesnokov EP; Feng JY; Porter DP; Götte M, Mechanism of inhibition of Ebola virus RNA-dependent RNA polymerase by remdesivir. Viruses 2019, 11, (4).

  62. 62.

    Ko WC; Rolain JM; Lee NY; Chen PL; Huang CT; Lee PI; Hsueh PR, Arguments in favour of remdesivir for treating SARS-CoV-2 infections. Int J Antimicrob Agents 2020, 105933.

  63. 63.

    Al-Tawfiq JA; Al-Homoud AH; Memish ZA, Remdesivir as a possible therapeutic option for the COVID-19. Travel Med Infect Dis 2020, 101615.

  64. 64.

    Sheahan, T. P.; Sims, A. C.; Leist, S. R.; Schäfer, A.; Won, J.; Brown, A. J.; Montgomery, S. A.; Hogg, A.; Babusis, D.; Clarke, M. O.; Spahn, J. E.; Bauer, L.; Sellers, S.; Porter, D.; Feng, J. Y.; Cihlar, T.; Jordan, R.; Denison, M. R.; Baric, R. S., Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020, 11, (1), 222.

  65. 65.

    Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269–71.

    CAS  PubMed  PubMed Central  Google Scholar 

  66. 66.

    Li H, Wang YM, Xu JY, Cao B. Potential antiviral therapeutics for 2019 novel coronavirus. Zhonghua. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43(0):E002.

    CAS  PubMed  Google Scholar 

  67. 67.

    Shiraki K; Daikoku T, Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 2020, 107512.

  68. 68.

    Goldhill DH, Te Velthuis AJW, Fletcher RA, Langat P, Zambon M, Lackenby A, et al. The mechanism of resistance to favipiravir in influenza. Proc Natl Acad Sci U S A. 2018;115(45):11613–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  69. 69.

    Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013;100(2):446–54.

    CAS  PubMed  Google Scholar 

  70. 70.

    Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  71. 71.

    Guedj, J.; Piorkowski, G.; Jacquot, F.; Madelain, V.; Nguyen, T. H. T.; Rodallec, A.; Gunther, S.; Carbonnelle, C.; Mentré, F.; Raoul, H.; de Lamballerie, X., Antiviral efficacy of favipiravir against Ebola virus: a translational study in cynomolgus macaques. PLoS Med 2018, 15, (3), e1002535.

  72. 72.

    Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antivir Res. 2018;153:85–94.

    CAS  PubMed  Google Scholar 

  73. 73.

    Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.

    PubMed  Google Scholar 

  74. 74.

    Potard V, Canestri A, Gallien S, Costagliola D. Use of darunavir in HIV-1-infected individuals in routine clinical practice from 2012 to 2016 in France. J Antimicrob Chemother. 2019;74(11):3305–14.

    CAS  PubMed  Google Scholar 

  75. 75.

    Spagnuolo V, Castagna A, Lazzarin A. Darunavir for the treatment of HIV infection. Expert Opin Pharmacother. 2018;19(10):1149–63.

    CAS  PubMed  Google Scholar 

  76. 76.

    Llibre, J. M., Development of darunavir over the entire spectrum of HIV infection. Enferm Infecc Microbiol Clin 2018, 36 Suppl 2, 3–9.

  77. 77.

    Deeks ED. Darunavir/cobicistat/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78(10):1013–24.

    CAS  PubMed  Google Scholar 

  78. 78.

    Deeks ED. Bictegravir/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2018;78(17):1817–28.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. 79.

    Greig SL, Deeks ED. Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide: a review in HIV-1 infection. Drugs. 2016;76(9):957–68.

    CAS  PubMed  Google Scholar 

  80. 80.

    Muller JT; Al Khalili Y, Emtricitabine. In StatPearls, StatPearls Publishing. Copyright © 2020, StatPearls Publishing LLC: Treasure Island (FL), 2020.

  81. 81.

    Shafi H, Reddy DVS, Khan T, Ranjan R, Srivastava A, Vaishya S, et al. Dehydroascorbate-derivatized chitosan particles for targeting antimalarial agents to infected erythrocytes. Int J Pharm. 2017;524(1–2):205–14.

    CAS  PubMed  Google Scholar 

  82. 82.

    Fukuda MM, Krudsood S, Mohamed K, Green JA, Warrasak S, Noedl H, et al. A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria. PLoS One. 2017;12(11):e0187376.

    PubMed  PubMed Central  Google Scholar 

  83. 83.

    Baruah UK, Gowthamarajan K, Ravisankar V, Karri V, Simhadri PK, Singh V. Optimisation of chloroquine phosphate loaded nanostructured lipid carriers using Box-Behnken design and its antimalarial efficacy. J Drug Target. 2018;26(7):576–91.

    CAS  PubMed  Google Scholar 

  84. 84.

    Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. Lancet Infect Dis. 2011;11(9):677–83.

    CAS  PubMed  Google Scholar 

  85. 85.

    Yao X; Ye F; Zhang M.; Cui C; Huang B; Niu P; Liu X; Zhao L; Dong E; Song C; Zhan S; Lu R; Li H; Tan W; Liu D, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020.

  86. 86.

    Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–3.

    CAS  Google Scholar 

  87. 87.

    Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020, 43, (0), E019.

  88. 88.

    Song P, Karako T. COVID-19: real-time dissemination of scientific information to fight a public health emergency of international concern. Biosci Trends. 2020;14(1):1–2.

    CAS  PubMed  Google Scholar 

  89. 89.

    Hydroxychloroquine. In LiverTox: clinical and research information on drug-induced liver injury, National Institute of Diabetes and Digestive and Kidney Diseases: Bethesda (MD), 2012.

  90. 90.

    Hu C, Lu L, Wan JP, Wen C. The pharmacological mechanisms and therapeutic activities of hydroxychloroquine in rheumatic and related diseases. Curr Med Chem. 2017;24(20):2241–9.

    CAS  PubMed  Google Scholar 

  91. 91.

    Schrezenmeier E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16(3):155–66.

    CAS  PubMed  Google Scholar 

  92. 92.

    Plantone D, Koudriavtseva T. Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review. Clin Drug Investig. 2018;38(8):653–71.

    CAS  PubMed  Google Scholar 

  93. 93.

    Shippey EA, Wagler VD, Collamer AN. Hydroxychloroquine: an old drug with new relevance. Cleve Clin J Med. 2018;85(6):459–67.

    PubMed  Google Scholar 

  94. 94.

    Khalili H, Dastan F, Dehghan Manshadi SA. A case report of hearing loss post use of hydroxychloroquine in a HIV-infected patient. Daru. 2014;22(1):20.

    PubMed  PubMed Central  Google Scholar 

  95. 95.

    Cao B, Parnell LA, Diamond MS, Mysorekar IU. Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice. J Exp Med. 2017;214(8):2303–13.

    CAS  PubMed  PubMed Central  Google Scholar 

  96. 96.

    Colson P; Rolain JM; Lagier JC; Brouqui P; Raoult D, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020, 105932.

  97. 97.

    Gautret P; Lagier JC; Parola P; Hoang VT; Meddeb L; Mailhe M; Doudier B; Courjon J; Giordanengo V; Vieira VE; Dupont HT; Honoré S; Colson P; Chabrière E; La Scola B; Rolain JM; Brouqui P; Raoult D, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents 2020, 105949.

  98. 98.

    Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. 99.

    Sahraei Z; Shabani M; Shokouhi S; Saffaei A, Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. Int J Antimicrob Agents 2020, 105945.

  100. 100.

    Snell LM, McGaha TL, Brooks DG. Type I interferon in chronic virus infection and cancer. Trends Immunol. 2017;38(8):542–57.

    CAS  PubMed  Google Scholar 

  101. 101.

    Sen N; Sung P; Panda A; Arvin AM, Distinctive roles for type I and type II interferons and interferon regulatory factors in the host cell defense against Varicella-Zoster virus. J Virol 2018, 92, (21).

  102. 102.

    Li HS, Kuok DIT, Cheung MC, Ng MMT, Ng KC, Hui KPY, et al. Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East respiratory syndrome coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model. Antivir Res. 2018;155:89–96.

    CAS  PubMed  Google Scholar 

  103. 103.

    Snyder B, Goebel S, Koide F, Ptak R, Kalkeri R. Synergistic antiviral activity of sofosbuvir and type-I interferons (α and β) against Zika virus. J Med Virol. 2018;90(1):8–12.

    CAS  PubMed  Google Scholar 

  104. 104.

    Sanmartí R, Ruiz-Esquide V, Bastida C, Soy D. Tocilizumab in the treatment of adult rheumatoid arthritis. Immunotherapy. 2018;10(6):447–64.

    PubMed  Google Scholar 

  105. 105.

    Ahn SS, Jung SM, Song JJ, Park YB, Park JY, Lee SW. Safety of tocilizumab in rheumatoid arthritis patients with resolved hepatitis B virus infection: data from real-world experience. Yonsei Med J. 2018;59(3):452–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  106. 106.

    Hashizume M, Tan SL, Takano J, Ohsawa K, Hasada I, Hanasaki A, et al. Tocilizumab, a humanized anti-IL-6R antibody, as an emerging therapeutic option for rheumatoid arthritis: molecular and cellular mechanistic insights. Int Rev Immunol. 2015;34(3):265–79.

    CAS  PubMed  Google Scholar 

  107. 107.

    Sheppard M, Laskou F, Stapleton PP, Hadavi S, Dasgupta B. Tocilizumab (Actemra). Hum Vaccin Immunother. 2017;13(9):1972–88.

    PubMed  PubMed Central  Google Scholar 

  108. 108.

    Jones SA, Scheller J, Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest. 2011;121(9):3375–83.

    CAS  PubMed  PubMed Central  Google Scholar 

  109. 109.

    Ramamoorthy S, Cidlowski JA. Corticosteroids: mechanisms of action in health and disease. Rheum Dis Clin N Am. 2016;42(1):15–31 vii.

    Google Scholar 

  110. 110.

    Meijer OC, Koorneef LL, Kroon J. Glucocorticoid receptor modulators. Ann Endocrinol. 2018;79(3):107–11.

    Google Scholar 

  111. 111.

    Whittier X, Saag KG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin N Am. 2016;42(1):177–89 x.

    Google Scholar 

  112. 112.

    Zhou YH; Qin YY; Lu YQ; Sun F; Yang S; Harypursat V; Tang SQ; Huang YQ; He XQ; Zeng YM.; Li Y; Xu XL; Zhao T; Chen YK, Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial. Chin Med J 2020.

  113. 113.

    Guo T; Fan Y; Chen M; Wu X; Zhang L; He T; Wang H; Wan J; Wang X; Lu Z, Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020.

  114. 114.

    Hu H; Ma F; Wei X; Fang Y, Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J 2020.

  115. 115.

    Zhang B; Liu S; Tan T; Huang W; Dong Y; Chen L; Chen Q; Zhang L; Zhong Q; Zhang X; Zou Y; Zhang S, Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest 2020.

Download references

Funding

This work was supported by the Scientific Research Project of National Natural Science Foundation of China (Nos. 81872979 and 81973439).

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Zhibin Wang or Chunjuan Yang.

Ethics declarations

Conflict of Interest

The authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Fan, L., Jiang, S., Yang, X. et al. COVID-19 Drug Treatment in China. Curr Pharmacol Rep (2020). https://doi.org/10.1007/s40495-020-00218-5

Download citation

Keywords

  • COVID-19
  • SARS-CoV-2
  • Medical treatment
  • New drug research and development